Skip to main content
. Author manuscript; available in PMC: 2020 Mar 30.
Published in final edited form as: Biomed Pharmacother. 2019 Aug 7;118:109323. doi: 10.1016/j.biopha.2019.109323

Fig. 11.

Fig. 11.

Electrocardiographic parameters of female 4T1 breast tumor-bearing BALB/c mice treated with DOX, SpHL-DOX, or SpHL-DOX-Fol. Each treatment was intravenously administered 4 times, every 3 days, at a dose of 5 mg/kg. (A) QT interval. (B) QTc interval. Data are expressed as the mean ± standard deviation of the mean (n = 7). All data were analyzed by one-way ANOVA analysis of variance followed by Tukey’s post-test. aRepresents statistical differences (P < 0.05) between baseline and DOX treatment after administration of the dose 4. bRepresents statistical differences (P < 0.05) between DOX and SpHL-DOX or SpHL-DOX-Fol treatments after administration of the dose 4.